title: Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme.
abstract: METHODS
  The Philippines ranks eighth among 27 priority countries for multidrug-resistant TB (MDR-TB).
  
  
  OBJECTIVE
  To describe a model of public-private partnership in MDR-TB management.
  
  
  METHODS
  An exploratory study of integrating MDR-TB management initiated in private-public mix DOTS into the National TB Programme (NTP).
  
  
  RESULTS
  Recognising that MDR-TB was a threat to DOTS, the Tropical Disease Foundation initiated MDR-TB management in 1999. An official mandate for the integration of MDR-TB services into the NTP was issued by the Department of Health in 2008. With an increased government budget augmented by support from the Global Fund to Fight AIDS, Tuberculosis and Malaria, 1294 MDR-TB patients were placed on treatment from 1999 to 2008. The treatment success rate improved from 64% in 1999 to 75% in 2005. There are now five MDR-TB treatment centres with 181 treatment sites in Metro Manila, and three culture centres. People trained include 12 master trainers, 31 trainers, 25 treatment centre and 381 treatment site staff.
  
  
  CONCLUSIONS
  Mainstreaming into the NTP of this unique model of MDR-TB management through a dynamic public-private collaboration can be considered best practice in implementation science of an evidence-based intervention leading to change in health care policy and practice.
authors.affiliation: Tropical Disease Foundation, Philippine Institute of Tuberculosis, Makati City, Philippines. mameldquelapio@tdf.org.ph
authors.forename: M I D
authors.initials: MI
authors.lastname: Quelapio
authors.forename: N R C
authors.initials: NR
authors.lastname: Mira
authors.forename: R B
authors.initials: RB
authors.lastname: Orillaza-Chi
authors.forename: V
authors.initials: V
authors.lastname: Belen
authors.forename: N
authors.initials: N
authors.lastname: Muñez
authors.forename: R
authors.initials: R
authors.lastname: Belchez
authors.forename: G E
authors.initials: GE
authors.lastname: Egos
authors.forename: M
authors.initials: M
authors.lastname: Evangelista
authors.forename: R
authors.initials: R
authors.lastname: Vianzon
authors.forename: T E
authors.initials: TE
authors.lastname: Tupasi
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D004196:Disease Outbreaks / Q000517:prevention & control*; D019981:Health Care Sector / Q000458:organization & administration*; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods*; D010679:Philippines / Q000453:epidemiology; D015397:Program Evaluation; D012189:Retrospective Studies; D018088:Tuberculosis, Multidrug-Resistant / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D000995:Antitubercular Agents